AstraZeneca adds to obesity drug race, but Eli Lilly remains in lead
remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). On Thursday, AstraZeneca said it paid $185 million upfront to acquire the rights to an experimental weight-loss pill from Eccogene, a Chinese biotech startup. AstraZeneca hopes to…#astrazeneca #azn #elililly #jimcramer #danish #novonordisk #nvo #club #zepbound #novoozempic
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: AstraZeneca | Biotechnology | China Health | Denmark Health | Eating Disorders & Weight Management | Health | Obesity | Weight Loss